



JIN-JIAN LU

Ph.D
Professor
Assistant Director

Primary Unit
SKL of Quality Research in Chinese Medicine
Institute of Chinese Medical Sciences
Academic Home
Department of Pharmaceutical Sciences
Faculty of Health Sciences
University of Macau
Room 5005a, 5F, N22, Avenida da Universidade
Taipa, Macao, China
Email: jinjianlu@um.edu.mo
Phone: 853-88224674; Fax: 853-28841358
Mobile: 853-62193428; 86-15344893428
<https://sklqrcm.um.edu.mo/jin-jian-lu/>
https://www.researchgate.net/profile/Jin-Jian_Lu

EDUCATION

- **Ph.D, Pharmacology**
7/2009, Shanghai Institute of *Materia Medica*, Chinese Academy of Sciences
- **BS, Biology**
7/2004, College of Chemistry and Life Sciences, Zhejiang Normal University

WORK EXPERIENCE

- **Professor & Assistant Director**
8/2024 to present, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau
- **Associate Professor & Assistant Director**
7/2022 to 8/2024, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau
- **Associate Professor & Coordinator of Chinese Medicinal Science Programme**
8/2018 to 6/2022, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau
- **Assistant Professor & Coordinator of Chinese Medicinal Science Programme**
8/2014 to 8/2018, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau
- **Visiting Project Scientist**
6/2014 to 8/2014, Cedars–Sinai Medical Centre
- **Assistant Professor**
8/2012 to 8/2014, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau
- **Postdoctoral Fellow**
9/2010 to 8/2012, Institute of Chinese Medical Sciences, University of Macau
- **Lecturer & Associate Professor**
7/2009 to 8/2012, College of Life Sciences, Zhejiang Chinese Medical University

TEACHING EXPERIENCE

- **UNIVERSITY OF MACAU**
 - 1) **Ph.D's Degree Programme**
Drug Discovery (2016/2017, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022, 2022/2023, 2023/2024); Drug Targets and Drug Screening (2014/2015, 2015/2016); System Pharmacology (2013/2014); University Teaching (2015/2016)
 - 2) **Master's Degree Programme**
Targets and Models for Drug Screen (2014/2015, 2015/2016, 2016/2017, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022, 2023/2024); Progress in Contemporary Study of Chinese Medicine (2015/2016, 2016/2017, 2017/2018, 2018/2019, 2019/2020, 2020/2021, 2021/2022, 2022/2023);

Phytochemistry (2012/2013, 2013/2014); Introduction to Research in Chinese Medicinal Science (2010/2011, 2011/2012, 2013/2014); Medical Information Technology (2012/2013)

3) **Bachelor's Degree Programme**

Drug Discovery and Development (2023/2024, 2024/2025); Pharmacology (2023/2024); Pharmacology Laboratory (2023/2024); Cancer Biology (2013/2014, 2014/2015); General Microbiology (2012/2013, 2013/2014, 2014/2015); General Microbiology Laboratory (2012/2013, 2013/2014, 2014/2015); Research Design and Data Analysis for Bioscientists (2012/2013, 2013/2014); Wonders in Life Science and Health (General Education Course, 2013/2014, 2014/2015)

• **ZHEJIANG CHINESE MEDICAL UNIVERSITY**

1) **Bachelor's Degree Programme**

Biochemistry (2009/2010); Biochemistry Laboratory (2009/2010); Scientific Instruments (2009/2010)

RESEARCH INTERESTS

- Leading compounds discovery for cancer therapy and mechanism study for the active chemicals.
- Screening, mechanistic study and application of immune checkpoint regulators for cancer treatment.
- Mechanistic study of drug resistance for the targeted therapy drugs.

RESEARCH PROJECTS

- 1) Science and Technology Development Fund, Macao S.A.R (FDCT). Structural modification of lycorine and its mechanism of enhancing antitumor activity of PD-L1 antibody. 0015-2022-A1. Dec 17, 2022 to Dec 16, 2025. 2,090,000 MOP. PI.
- 2) Science and Technology Development Fund, Macao S.A.R (FDCT). The identification and the pre-clinical study of novel agents to enhance cancer immunotherapy by improving tumor microenvironment. 0053-2021-AGJ. Jul 17, 2022 to Jul 16, 2024. 1,130,000 MOP. PI.
- 3) Science and Technology Development Fund, Macao S.A.R (FDCT). Identification of co-suppressors and naturally-derived small molecule inhibitors of CD47 immune checkpoint. 0129-2019-A3. May 22, 2020 to May 23, 2023. 2,077,000 MOP. PI.
- 4) National Natural Science Foundation of China. Anti-cancer mechanisms for ginsenoside Rh2 combined with everolimus on non-small cell lung cancer via mediating paraptosis. 81973516. Jan 2020 to Dec 2023. 550,000 RMB. PI.
- 5) State Key Laboratory of Drug Research. The regulatory network of c-MYC in paraptosis based on combinational therapy. SIMM2004KF-05. 2020.4 – 2021.4. 100,000 RMB. PI.
- 6) State Key Laboratory of Natural Medicines. Screening and optimization of anti-PD-L1 inhibitors from natural products for lung cancer treatment. SKLNMKF202006. Jan 2020 to Dec 2021. 100,000 RMB. PI.
- 7) Science and Technology Development Fund, Macao S.A.R (FDCT). PD-L1 regulators from Chinese medicines for the treatment of non-small cell lung cancer. 176-2017-A3. May 2018 to Nov 2020. 1,628,000 MOP. PI.
- 8) University of Macau. Investigation on mechanisms of epithelial-mesenchymal transition mediated resistance to osimertinib and the combination therapy strategy. MYRG2018-00165-ICMS. Sep 2018 to Aug 2021. 888,900 MOP. PI.
- 9) Science and Technology Development Fund, Macao S.A.R (FDCT). Co-targeting EGFR and mTOR for non-small cell lung cancer treatment. 024/2016/A1. Jul 2016 to Jul 2019. 1,780,000 MOP. PI.
- 10) Science and Technology Development Fund, Macao S.A.R (FDCT). Targets- and synergy-based anticancer drugs: design and biological evaluation. 038/2014/A1. Jan 2015 to Jan 2018. 1,539,000 MOP. PI.
- 11) Science and Technology Development Fund, Macao S.A.R (FDCT). The effects and molecular mechanisms of platycodin D-induced autophagy in cancer cells. 070/A/2013. Jan 2014 to Jan 2016. 381,000 MOP. PI.
- 12) University of Macau. Design and biological evaluation of folate receptor-targeted and hypoxia-activated new anticancer compounds. MYRG2015-00091-ICMS-QRCM. Apr 2015 to Mar 2018. 1,300,000 MOP. PI.

- 13) University of Macau. Combination of autophagy inhibitors and glycyrrhetic acid-modified poly(ethylene glycol)-chitosan nanoparticles loaded doxorubicin for the hepatocellular carcinoma therapy. MYRG2015-00101-ICMS-QRCM. Apr 2015 to Mar 2018. 780,000 MOP. PI.
- 14) University of Macau. Targets- and synergy-based anticancer drugs: design and biological evaluation. MRG024-LJJ-2015-ICMS. Jan 2015 to Jan 2018. 513,000 MOP. PI.
- 15) University of Macau. The effects and molecular mechanisms of platycodin D-induced autophagy in cancer cells. MRG008-LJJ2014-ICMS. Jan 2014 to Jan 2016. 114,300 MOP. PI.
- 16) University of Macau. Study of the antitumor potentials and mechanisms of combined with clinical drugs and active compounds isolated from Chinese medicine. SRG026-ICMS13-LJJ. Jan 2013 to Dec 2014. 100,000 MOP. PI.
- 17) State Key Laboratory of Natural Medicines. Combined platycodin D and everolimus for non-small cell lung cancer treatment. SKLNMKF201605. Jan 2016 to Dec 2017. 100,000 RMB. PI.
- 18) State Key Laboratory of Drug Research. Mechanism study of platycodin D-triggered autophagy and its application in cancer treatment. SIMM1403KF-11. Mar 2014 to Mar 2015. 80,000 RMB. PI.
- 19) National Natural Science Foundation of China. Study of the anti-cancer mechanisms of dihydroartemisinin based on the mitochondrial proteomics. 81001450. Jan 2011 to Dec 2013. 200,000 RMB. PI.
- 20) Administration of Traditional Chinese Medicine of Zhejiang Province. Study of the anti-liver cancer effects and the molecular mechanisms of Platycodin D. 2012ZA028. Jun 2012 to May 2014. 30,000 RMB. PI.
- 21) Department of Education of Zhejiang Province. Study of the protein expression changes of dihydroartemisinin on the mitochondrial of liver cancer cells. Y201016139. Oct 2010 to Oct 2012. 10,000 RMB. PI.
- 22) Zhejiang Chinese Medical University. The effects of combined therapy using dihydroartemisinin and chemotherapeutic drugs based on endoplasmic reticulum stress. 2009ZZ04. Nov 2009 to Nov 2011. 15,000 RMB. PI.

PUBLICATION

• JOURNAL CONTRIBUTIONS

Dr. Lu has published more than 200 scientific papers in the professional journals, such as *J Hematol Oncol*, *Acta Pharm Sin B*, *Pharmacol Ther*, *Cancer Lett*, *Redox Biol*, *etc.* (Citations 10000+, h index=54, Scopus)

* *Corresponding or co-corresponding author*, #*Co-first author*

- 1) Zhang LL, Zhang DJ, Shi JX, Huang MY, Yu JM, Chen XJ, Wei X, Zou L*, **Lu JJ***. Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products. *Phytomedicine*. 2024, 132: 155828.
- 2) Zheng Y, Wang C, Liu W, Chen J, Sun Y, Chang D, Wang H, Xu W, **Lu JJ***, Zhou X*, Huang M*. Upregulation of Nrf2 signaling: A key molecular mechanism of Baicalin's neuroprotective action against diabetes-induced cognitive impairment. *Biomed Pharmacother*. 2024, 174: 116579.
- 3) Zhang LL*, **Lu JJ***. Combination strategies for first-line treatment of patients with unresectable hepatocellular carcinoma: prospect of natural products. *Chin J Nat Med*. 2024, 22(1): 1-3.
- 4) Xu CC, Lin YF, Huang MY, Zhang XL, Wang P, Huang MQ*, **Lu JJ***. Paraptosis: a non-classical paradigm of cell death for cancer therapy. *Acta Pharmacol Sin*. 2024, 45(2): 223-37.
- 5) Zhang QY, Ding W, Mo JS, Ou-Yang SM, Lin ZY, Peng KR, Liu GP, **Lu JJ**, Yue PB, Lei JP, Wang YD, Zhang XL*. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. *Acta Pharmacol Sin*. 2024, In Press.
- 6) Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T*, Huang M*, **Lu JJ***. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8⁺ T cells via increasing intratumoral CXCL10. *Pharmacol Res*. 2023, 198: 106988.
- 7) He X, Fu J, Lyu W, Huang M, Mo J, Cheng Y, Xu Y, Zheng L, Zhang X, Qi L, Zhang L, Zheng Y, Huang M*, Ni L*, **Lu JJ***. Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells. *Chin J Nat Med*. 2023, 21(11): 842-51.
- 8) Ye ZH, Yu WB, Huang MY, Chen J, **Lu JJ***. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. *Acta Pharm Sin B*. 2023, 13(4): 1467-87.

- 9) Yu WB, Chen YC, Huang CY, Ye ZH, Shi W, Zhu H, Shi JJ, Chen J, **Lu JJ***. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. *Front Med*. 2023, 17(1): 105-18.
- 10) He XL, Lyu WY, Li XY, Zhao H, Qi L*, **Lu JJ***. Identification of glycogen phosphorylase L as a potential target for lung cancer. *Med Oncol*. 2023, 40(7): 211.
- 11) Li XY, He XY, Zhao H, Qi L*, **Lu JJ***. Identification of a novel therapeutic target for lung cancer: Mitochondrial ribosome protein L9. *Pathol Res Pract*. 2023, 248: 154625.
- 12) Lin Y, Li S, Chen T, Lin Y, Cheng Z, Ni L*, **Lu JJ***, Huang M*. Phytochemical compositions and biological activities of the branches and leaves of *Ormosia hosiei* Hemsl. et Wils. *J Pharm Biomed Anal*. 2023, 226: 115238.
- 13) Lu J, Li J, Lin Z, Li H, Lou L, Ding W, Ouyang S, Wu Y, Wen Y, Chen X, Yue P, Wang Y, Liu P, **Lu JJ***, Zhang J*, Feng W*, Zhang X*. Reprogramming of TAMs via the STAT3/CD47-SIRP α axis promotes acquired resistance to EGFR-TKIs in lung cancer. *Cancer Lett*. 2023, 564: 216205.
- 14) Wang X, Shi W, Wang X, **Lu JJ**, He P, Zhang H, Chen X*. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer. *Cell Death Discov*. 2023, 9(1): 355.
- 15) Yu J, Zhong B, Zhao L, Hou Y, Ai N, **Lu JJ**, Ge W, Chen X*. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis. *Drug Resist Updat*. 2023, 70: 100977.
- 16) Zhao L, Zhong B, Zhu Y, Zheng H, Wang X, Hou Y, **Lu JJ**, Ai N, Guo X, Ge W, Ma YY, Chen X*. Nitrovin (difurazone), an antibacterial growth promoter, induces ROS-mediated paraptosis-like cell death by targeting thioredoxin reductase 1 (TrxR1). *Biochem Pharmacol*. 2023, 210: 115487.
- 17) Li J, Wang Y, Wang L, Hao D, Li P, Su M, Zhao Z, Liu T, Tai L, **Lu JJ**, Di LJ*. Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer. *Int J Biol Sci*. 2023, 19(7): 2081-96.
- 18) Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, Ding W, Ouyang S, **Lu JJ**, Yue P, Wan G, Liu P, Zhang X*. Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. *Cancer Res*. 2023, 83(13): 2187-207.
- 19) Mo J, Deng L, Peng K, Ouyang S, Ding W, Lou L, Lin Z, Zhu J, Li J, Zhang Q, Wang P, Wen Y, Chen X, Yue P, **Lu JJ**, Zhu K, Zheng Y, Wang Y, Zhang X*. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. *J Hematol Oncol*. 2023, 16(1): 15.
- 20) Liu Q, **Lu JJ**, Hong HJ, Yang Q, Wang Y, Chen XJ*. Ophiopogon japonicus and its active compounds: A review of potential anticancer effects and underlying mechanisms. *Phytomedicine*. 2023, 113: 154718.
- 21) Chen MH, Leong F, Gao SJ, Chen X, **Lu JJ**, Lin LG, Wang Y, Chen XJ*. Comparison of Ophiopogon japonicus and Liriope spicata var. prolifera from Different Origins Based on Multi-Component Quantification and Anticancer Activity. *Molecules*. 2023, 28(3): 1045.
- 22) Han B, Zhai Y, Li X, Zhao H, Sun C, Zeng Y, Zhang W, **Lu JJ**, Kai G. Total flavonoids of *Tetrastigma hemsleyanum* Diels et Gilg inhibits colorectal tumor growth by modulating gut microbiota and metabolites. *Food Chem*. 2023, 410: 135361.
- 23) Ji QX, Zeng FY, Zhou J, Wu WB, Wang XJ, Zhang Z, Zhang GY, Tong J, Sun DY, Zhang JB, Cao WX, Shen FM, **Lu JJ**, Li DJ*, Wang P*. Ferroptotic stress facilitates smooth muscle cell dedifferentiation in arterial remodelling by disrupting mitochondrial homeostasis. *Cell Death Differ*. 2023, 30(2): 457-74.
- 24)
- 25) Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, Zhang LL, Chen X, Zhu H, **Lu JJ***. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. *MedComm*. 2022, 3(3): e152.
- 26) Chen YC, HE XL, Qi L, Shi W, Yuan LW, Huang MY, Xu YL, Chen X, Gu L, Zhang LL, **Lu JJ***. Myricetin inhibits interferon- γ -induced PD-L1 and IDO1 expression in lung cancer cells. *Biochem Pharmacol*. 2022, 197: 114940.
- 27) Shi W, Qi L, You XB, Chen YC, Xu YL, Yu WB, Huang MY, Zhao H*, **Lu JJ***. Identification of AHS1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and In Vitro Studies. *Curr Cancer Drug Targets*. 2022, In Press.
- 28) Chen YC, Shi W, Shi JJ*, **Lu JJ***. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective. *J Cancer Res Clin Oncol*. 2022, 148(1): 1-14.
- 29) Su MX, Xu YL, Jiang XM, Huang MY, Zhang LL, Yuan LW, Xu XH, Zhu Q, Gao JL, Lu JH, Chen X, Huang MQ, Wang Y, **Lu JJ***. c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers

- paraptosis upon the combination of everolimus and ginsenoside Rh2. *Acta Pharm Sin B*. 2022, 12(3): 1240-53.
- 30) He XL, Xu XH, Shi JJ, Huang M, Wang Y, Chen X, **Lu JJ***. Anticancer effects of ginsenoside Rh2: a systematic review. *Curr Mol Pharmacol*. 2022; 15(1): 179-89.
 - 31) Sun C, Zhao L, Wang X, Hou Y, Guo X, **Lu JJ**, Chen X*. Psoralidin, a natural compound from *Psoralea corylifolia*, induces oxidative damage mediated apoptosis in colon cancer cells. *J Biochem Mol Toxicol*. 2022, In Press.
 - 32) Zhong B, Zhao L, Yu J, Hou Y, Ai N, **Lu JJ**, Ge W, Chen X*. Exogenous iron impairs the anti-cancer effect of ascorbic acid both in vitro and in vivo. *J Adv Res*. 2022, In Press.
 - 33) Xu Y, Shi W, Feng L, Cao J, Feng Z, Zhang Q, **Lu JJ**, Ye Y, Lin L*. Anti-proliferative cassane-type diterpenoids from the seeds of *Caesalpinia minax*. *Nat Prod Res*. 2022, 36(4): 932-41.
 - 34) Dong Y, Zhu G, Wang SF, Keon KA, Rubinstein JL, Zeng SX, Zhang S, Chen QL, Fu J, Li M, Shen HM, **Lu JJ**, Chen XP, Lu JH*. Toosendanin, a novel potent vacuolar-type H⁺-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy. *Int J Biol Sci*. 2022, 18(7): 2684-702.
 - 35) Ye ZH, Jiang XM, Huang MY, Xu YL, Chen YC, Yuan LW, Huang CY, Yu WB, Chen X, **Lu JJ***. Regulation of CD47 expression by interferon-gamma in cancer cells. *Transl Oncol*. 2021, 14: 101162.
 - 36) Huang MY, Jiang XM, Wang BL, Sun Y, **Lu JJ***. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. *Pharmacol Ther*. 2021, 219: 107694.
 - 37) Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, **Lu JJ***. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. *Phytomedicine*. 2021, 80: 153394.
 - 38) Yu WB, Ye ZH, Chen X, Shi JJ*, **Lu JJ***. The development of small-molecule inhibitors targeting CD47. *Drug Discov Today*, 2021, 26(2): 561-68.
 - 39) Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, **Lu JJ***. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. *Acta Pharmacol Sin*. 2021, 42: 451-9.
 - 40) Xu XH, Chen YC, Xu YL, Feng ZL, Liu QY, Guo X, Lin LG, **Lu JJ***. Garcinone E blocks autophagy via lysosomal functional destruction in ovarian cancer cells. *World J TCM*. 2021, 7(2): 209-16.
 - 41) Wang WH, Yuan T, Qian MJ, Yan FJ, Yang L, He QJ, Yang B, **Lu JJ***, Zhu H*. Post-translational modification of KRAS: potential targets for cancer therapy. *Acta Pharmacol Sin*. 2021, 42(8): 1201-11.
 - 42) Huang XB, Yuan LW, Shao J, Yang Y, Liu Y, **Lu JJ***, Chen L*. Cytotoxic effects of flavonoids from root of *Sophora flavescens* in cancer cells. *Nat Prod Res*. 2021, 35(22): 4317-22.
 - 43) Klionsky DJ, ... **Lu JJ** ..., Tong CK. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy*. 2021, 17(1): 1-382.
 - 44) Hou Y, Liu R, Xia M, Sun C, Zhong B, Yu J, Ai N, **Lu JJ**, Ge W, Liu B*, Chen X*. Nannocystin ax, an eEF1A inhibitor, induces G1 cell cycle arrest and caspase-independent apoptosis through cyclin D1 downregulation in colon cancer *in vivo*. *Pharmacol Res*. 2021, 173: 105870.
 - 45) Zhong B, Yu J, Hou Y, Ai N, Ge W, **Lu JJ**, Chen X*. A novel strategy for glioblastoma treatment by induction of noptosis, an NQO1-dependent necrosis. *Free Radic Biol Med*. 2021, 166: 104-15.
 - 46) Wang M, Lin L, **Lu JJ**, Chen X. Pharmacological review of isobavachalcone, a naturally occurring chalcone. *Pharmacol Res*. 2021, 165: 105483.
 - 47) Sun C, Liu R, Xia M, Hou Y, Wang X, **Lu JJ**, Liu B*, Chen X*. Nannocystin Ax, a natural elongation factor 1α inhibitor from *Nannocystis* sp., suppresses epithelial-mesenchymal transition, adhesion and migration in lung cancer cells. *Toxicol Appl Pharmacol*. 2021, 420: 115535.
 - 48) Cao J, Xu Y, Lou R, Shi W, Chen J, Gan L, **Lu JJ**, Lin L. Cassane-Type Diterpenoids from the Seeds of *Caesalpinia bonduc* (L.) Roxb. *Chem Biodivers*. 2021, 18(9): e2100309.
 - 49) Li D, Zhang T, **Lu JJ**, Peng C*, Lin L*. Natural constituents from food sources as therapeutic agents for obesity and metabolic diseases targeting adipose tissue inflammation. *Crit Rev Food Sci Nutr*. 2021, 61(12): 1947-65.
 - 50) Chong CM, Zhong Z, Vong CT, Wang S, **Lu JJ**, Zhong H, Su H, Wang Y*. The potentials of *Uncariae Ramulus Cum Uncis* for treatment of migraine: Targeting CGRP in the trigeminovascular system. *Curr Neuropharmacol*. 2021, 19(7): 1090-100.
 - 51) Huang M, **Lu JJ**, Ding J. Natural Products in Cancer Therapy: Past, Present and Future. *Nat Prod Bioprospect*. 2021, 11: 5-13.

- 52) Zhang X, Zhang Q, Huang L, Liu M, Cheng Z, Zheng Y, Xu W, **Lu JJ**, Liu J, Huang M. Pien-Tze-Huang attenuates neuroinflammation in cerebral ischaemia-reperfusion injury in rats through the TLR4/NF- κ B/MAPK pathway. *Pharm Biol.* 2021; 59(1): 828-39.
- 53) Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, **Lu JJ***. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. *Biochem Pharmacol.* 2020, 175: 113921.
- 54) Huang CY, Ye ZH, Huang MY, **Lu JJ***. Regulation of CD47 expression in cancer cells. *Transl Oncol.* 2020, 13(12): 100862.
- 55) Zhang LL, Huang MY, Yang Y, Huang MQ, Shi JJ, Zou L*, **Lu JJ***. Bioactive platycodins from *Platycodonis Radix*: phytochemistry, pharmacological activities, toxicology and pharmacokinetics. *Food Chem.* 2020, 327: 127029.
- 56) Zhang LL, Bao H, Xu YL, Jiang XM, Li W, Zhou L, Lin LG*, **Lu JJ***. Phanginin R induces cytoprotective Aatophagy via JNK/c-Jun signaling pathway in non-small cell lung cancer A549 cells. *Anticancer Agents Med Chem.* 2020, 20(8): 982-8.
- 57) **Lu JJ***, Wang YT*. Identification of anti-cancer compounds from natural products. *Chin J Nat Med.* 2020, 18(7): 481-2.
- 58) Chen YC, Huang MY, Zhang LL, Feng ZL, Jiang XM, Yuan LW, Huang RY, Liu B, Yu H, Wang Y, Chen X, Lin LG, **Lu JJ***. Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. *Chin J Nat Med.* 2020, 18(7): 517-25.
- 59) Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, **Lu JJ***. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. *Acta Pharmacol Sin.* 2020, 41: 698-705.
- 60) Li A, Xiao X, Feng ZL, Chen X, Liu LJ, Lin LG*, **Lu JJ***, Zhang LL*. Nagilactone D ameliorates experimental pulmonary fibrosis in vitro and in vivo via modulating TGF- β /Smad signaling pathway. *Toxicol Appl Pharmacol.* 2020, 389: 114882.
- 61) Yu J, Zhong B, Jin L, Hou Y, Ai N, Ge W, Li L, Liu S, **Lu JJ**, Chen X*. 2-Methoxy-6-acetyl-7-methyljuglone (MAM) induced programmed necrosis in glioblastoma by targeting NAD(P)H: Quinone oxidoreductase 1 (NQO1). *Free Radic Biol Med.* 2020, 152: 336-47.
- 62) Yu J, Zhong B, Xiao Q, Du L, Hou Y, Sun HS, **Lu JJ**, Chen X*. Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds. *Pharmacol Ther.* 2020, 214: 107593.
- 63) Liu X, Zhang Y, Zhou GJ, Hou Y, Kong Q, **Lu JJ**, Zhang Q, Chen X*. Natural alkaloid 8-oxo-epiberberine inhibited TGF- β 1-triggred epithelial-mesenchymal transition by interfering Smad3. *Toxicol Appl Pharmacol.* 2020, 404: 115179.
- 64) Liu X, Zhang Y, Gao H, Hou Y, **Lu JJ**, Feng Y, Xu Q, Liu B, Chen X*. Induction of an MLKL mediated non-canonical necroptosis through reactive oxygen species by tanshinol A in lung cancer cells. *Biochem Pharmacol.* 2020, 171: 113684.
- 65) Ge Y, Zhang S, Wang J, Xia F, Wan JB, **Lu JJ**, Ye RD*. Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity. *FASEB J.* 2020, 34(5): 6920-33.
- 66) Zeng CM, Zhao CX, Ge FJ, Li YK, Cao J, Ying MD, **Lu JJ**, He QJ, Yang B, Dai XY*, Zhu H*. Machado-Joseph deubiquitinases: From cellular functions to potential therapy targets. *Front Pharmacol.* 2020, 1311.
- 67) Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, Qi Q, **Lu JJ**, Fan CL, Chen MF, Qi M, Li XB, Hong J, Zhang DM*, Ye WC*. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. *Signal Transduct Target Ther.* 2020, 5: 214.
- 68) Huang MY, Jiang XM*, Xu YL, Yuan LW, Chen YC, Cui G, Huang RY, Liu B, Wang Y, Chen X, **Lu JJ***. Platycodin D triggers the extracellular release of prograded death Ligand-1 in lung cancer cells. *Food Chem Toxicol.* 2019, 131: 110537.
- 69) Xu YL, Jiang XM, Zhang LL, Chen X, Huang ZJ, **Lu JJ***. Establishment and characterization of pemetrexed-resistant NCI-H460/PMT cells. *Anticancer Agents Med Chem.* 2019, 19(6):731-9.
- 70) Su MX, Zhang LL, Huang ZJ, Shi JJ, **Lu JJ***. Investigational hypoxia-activated prodrugs: Making sense of future development. *Curr Drug Targets.* 2019, 20(6): 668-78.
- 71) Zhang LL, Jiang XM, Huang MY, Feng ZL, Chen X, Wang Y, Li H, Li A, Lin LG*, **Lu JJ***. Nagilactone E suppresses TGF- β 1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells. *Phytomedicine.* 2019, 52: 32-9.

- 72) Huang LL, Zhang YP, Zhang XQ, Chen XP, Wang YT, **Lu JJ***, Huang MQ*. Therapeutic potential of Pien-Tze-Huang: A review on its chemical composition, pharmacology, and clinical application. *Molecules* 2019, 24(18): 3274.
- 73) Sun W, Yu J, Gao H, Wu X, Wang S, Hou Y, **Lu JJ**, Chen X*. Inhibition of lung cancer by 2-methoxy-6-acetyl-7-methyljuglone (MAM) through induction of necroptosis by targeting receptor-interacting protein 1 (RIP1). *Antioxid Redox Signal*. 2019, In Press.
- 74) Chen X*, Yu J, Zhong B, Lu J, **Lu JJ**, Li S, Lv Y. Pharmacological activities of dihydrotanshinone I, a natural product from *Salvia miltiorrhiza* Bunge. *Pharmacol Res*. 2019, In Press.
- 75) Wang A, Zhou F, Li D, **Lu JJ**, Wang Y, Lin L*. γ -Mangostin alleviates liver fibrosis through Sirtuin 3-superoxide-high mobility group box 1 signaling axis. *Toxicol Appl Pharmacol*. 2019, 363: 142-53.
- 76) Wang J, Wu MY, Su H, **Lu JJ**, Chen X, Tan J, Lu JH*. iNOS Interacts with Autophagy Receptor p62 and is Degraded by Autophagy in Macrophages. *Cells*. 2019, 8(10).
- 77) Cai CZ, Zhou HF, Yuan NN, Wu MY, Lee SM, Ren JY, Su HX, **Lu JJ**, Chen XP, Li M, Tan JQ, Lu JH*. Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. *Phytomedicine*. 2019, In Press.
- 78) Huang XJ, Li P, Yin ZQ, **Lu JJ**, Lin LG, Wang Y, Ye WC, Zhang QW*. Cablinosides A and B, two glycosidic phenylacetic acid derivatives from the leaves of *Pogostemon cablin*. *Chem Biodivers*. 2019, In Press.
- 79) Chong CM*, Su H, **Lu JJ**, Wang Y*. The effects of bioactive components from the rhizome of *Salvia miltiorrhiza* (Danshen) on the characteristics of Alzheimer's disease. *Chin Med*. 2019, 14: 19.
- 80) Wang Z, Linghu KG, Hu Y, Zuo H, Yi H, Xiong SH, **Lu JJ**, Chan G*, Yu H*, Huang RY. Deciphering the Pharmacological Mechanisms of the Huayu-Qiangshen-Tongbi Formula Through Integrating Network Pharmacology and In Vitro Pharmacological Investigation. *Front Pharmacol*. 2019, 10: 1065.
- 81) Chen XM, Zhao Y, Wu XD, Wang MJ, Yu H, **Lu JJ**, Hu YJ, Huang QC, Huang RY, Lu CJ. Novel findings from determination of common expressed plasma exosomal microRNAs in patients with psoriatic arthritis, psoriasis vulgaris, rheumatoid arthritis, and gouty arthritis. *Discov Med*. 2019, 28(151): 47-68.
- 82) Xiao X, Li S, Zhang X, **Lu JJ**, Wang W, Zhou S, Zhang J, Wang R*, Li A*. HHQ-4, a quinoline derivate, preferentially inhibits proliferation of glucose-deprived breast cancer cells as a GRP78 down-regulator. *Toxicol Appl Pharmacol*. 2019, 373: 10-25.
- 83) Wang XB*, **Lu JJ**. Overview on good pharmacological practice on Chinese medicine research. *Mod Trad Chin Med Mater Med*. 2019, 21(9): 1846-54.
- 84) Cao WX, Li T, Tang ZH, Zhang LL, Wang ZY, Guo X, Su MX, Chen X, **Lu JJ***. MLKL mediates apoptosis via a mutual regulation with PERK/eIF2 α pathway in response to reactive oxygen species generation. *Apoptosis*. 2018, 23(9-10): 521-31.
- 85) Huang MY, Zhang LL, Ding J, **Lu JJ***. Anticancer drug discovery from Chinese medicinal herbs. *Chin Med*. 2018, 13: 35. *(Invited Review)*
- 86) Zhang LL, Feng ZL, Su MX, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, **Lu JJ***. Downregulation of Cyclin B1 mediates nagilactone E-induced G2 phase cell cycle arrest in non-small cell lung cancer cells. *Eur J Pharmacol*. 2018, 830: 17-25.
- 87) Li T, Jiang HL, Tong YG, **Lu JJ***. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery. *J Hematol Oncol*. 2018, 11: 59.
- 88) Tang ZH, **Lu JJ***. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. *Cancer Lett*. 2018, 420: 242-6.
- 89) Tang ZH, Cao WX, Guo X, Dai XY, Lu JH, Chen X, Zhu H, **Lu JJ***. Identification of a novel autophagic inhibitor cepharanthine to enhance the anti-cancer property of dacomitinib in non-small cell lung cancer. *Cancer Lett*. 2018, 412: 1-9.
- 90) Tang ZH, Su MX, Guo X, Jiang XM, Jia L, Chen X, **Lu JJ***. Increased expression of IRE1 α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells. *Anticancer Agents Med Chem*. 2018, 18: 550-5.
- 91) Yu J, Gao H, Wu C, Xu QM, **Lu JJ**, Chen X*. Diethyl blechnic, a novel natural product isolated from *Salvia miltiorrhiza* Bunge, inhibits doxorubicin-induced apoptosis by inhibiting ROS and activating JNK1/2. *Int J Mol Sci*. 2018, 19(6): 1809.
- 92) Niu Y, Yuan R, Gao H, Kong Q, **Lu JJ**, Chen X*. 2-Methoxy-6-acetyl-7-methyljuglone (MAM) induces iNOS/NO-mediated DNA damage response through activation of MAPKs pathways. *Anticancer Agents Med Chem*. 2018, 18(6): 903-13.

- 93) Yu J, Wang C, Kong Q, Wu X, **Lu JJ**, Chen X*. Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. *Phytomedicine*. 2018, 40: 125-39.
- 94) Luo W, Liu X, Sun W, **Lu JJ**, Wang Y*, Chen X*. Toosendanin, a natural product, inhibited TGF- β 1-induced epithelial-mesenchymal transition through ERK/Snail pathway. *Phytother Res*. 2018, 32(10): 2009-20.
- 95) Luo WW, Zhao WW, **Lu JJ**, Wang YT*, Chen XP*. Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells. *Chin J Nat Med*. 2018, 16(1): 10-9.
- 96) Lv T, Wu J, Kang F, Wang T, Wan B, **Lu JJ**, Zhang Y, Huang Z*. Synthesis and evaluation of O²-derived diazeniumdiolates activatable via bioorthogonal chemistry reactions in living cells. *Org Lett*. 2018, 20: 2164-7.
- 97) Xing L, Zhang JL, Zhou TJ, He YJ, Cui PF, Gong JH, Sun M, **Lu JJ**, Huang Z, Jin L*, Jiang HL*. A novel design of a polynuclear co-delivery system for safe and efficient cancer therapy. *Chem Commun*. 2018, 54(63): 8737-40.
- 98) Cai X, Chen XM, Xia X, Bao K, Wang RR, Peng JH, Liu HJ, Yang QW, Yan JY, Wang MJ, Yu H, **Lu JJ**, Hu YJ, Jakobsson PJ*, Wen ZH*, Huang RY*, Huang QC. The Bone-Protecting Efficiency of Chinese Medicines Compared With Western Medicines in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Comparative Studies. *Front Pharmacol*. 2018, 9: 914.
- 99) Jiang XM, Xu YL, Huang MY, Zhang LL, Su MX, Chen XP, **Lu JJ***. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. *Acta Pharmacol Sin*. 2017, 38(11): 1512-20.
- 100) Wang YF, Tang ZH, Li T, Xu XH, Chen XP, Wang Y, Wang YT, **Lu JJ***. Baicalein protects tert-butyl hydroperoxide-induced hepatotoxicity dependent of reactive oxygen species removal. *Mol Med Rep*. 2017, 16(6): 8392-8.
- 101) Lin HH, Zhang LL, Yan R, **Lu JJ***, Hu YJ*. Network analysis of drug–target interactions: A study on FDA-approved new molecular entities between 2000 to 2015. *Sci Rep*. 2017, 7: 12230.
- 102) Xu XH, Liu QY, Li T, Liu JL, Chen X, Huang L, Qiang WA, Chen X, Wang Y, Lin LG*, **Lu JJ***. Garcinone E induces apoptosis and inhibits migration and invasion in ovarian cancer cells. *Sci Rep*. 2017, 7: 10718.
- 103) Zhang LL, Xu W, Xu YL, Chen XP, Huang MQ*, **Lu JJ***. Therapeutic potential of Rhizoma Alismatis: A review on ethnomedicinal application, phytochemistry, pharmacology, and toxicology. *Ann N Y Acad Sci*. 2017, 1401(1): 90-101. (*Invited Review*)
- 104) Tang ZH, Guo X, Cao WX, Chen X, **Lu JJ***. Fangchinoline accumulates autophagosomes by inhibiting autophagic degradation and promoting TFEB nuclear translocation. *RSC Adv*. 2017, 7: 42597-605.
- 105) Li T, Chen X, Dai XY, Wei B, Weng QJ, Chen X, Ouyang DF, Yan R, Huang ZJ, Jiang HL, Zhu H, **Lu JJ***. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. *Toxicol Appl Pharmacol*. 2017, 330: 65-73.
- 106) Feng ZL, Zhang LL, Zhen, YD, Liu QY, Liu JX, Feng L, Huang L, Zhang QW, **Lu JJ***, Lin LG*. Norditerpenoids and dinorditerpenoids from the seeds of Podocarpus nagi as cytotoxic agents and autophagy inducers. *J Nat Prod*. 2017, 80: 2110-7.
- 107) Tang ZH, Cao WX, Wang ZY, Lu JH, Liu B, Chen XP, **Lu JJ***. Induction of reactive oxygen species-stimulated distinctive autophagy by chelerythrine in non-small cell lung cancer cells. *Redox Biol*. 2017, 12: 367-76.
- 108) Tang ZH, Cao WX, Su MX, Chen X, **Lu JJ***. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. *Toxicol Appl Pharmacol*. 2017, 321: 18-26.
- 109) Xu XH, Zhang LL, Wu GS, Chen X, Li T, Chen X*, Wang YT, **Lu JJ***. Solasodine induces apoptosis, affects autophagy, and attenuates metastasis in ovarian cancer cells. *Planta Med*. 2017, 83(3-4): 254-60.
- 110) Wang YF, Xu YL, Tang ZH, Li T, Zhang LL, Chen X, Lu JH, Leung CH, Ma DL, Qiang WA, Wang YT, **Lu JJ***. Baicalein induces Beclin 1- and extracellular signal-regulated kinase- dependent autophagy in ovarian cancer cells. *Am J Chin Med*. 2017, 45(1): 123-36.
- 111) Xu W, Zhang Y, Zhou C, Tai Y, Zhang X, Liu J, Sha M, Huang M*, Zhu Y, Peng J, **Lu JJ***. Simultaneous quantification six active compounds in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study of Pien-Tze-Huang. *J Chromatogr B*. 2017, 1061-1062: 314-21.
- 112) Yuan R, Hou Y, Sun W, Yu J, Liu X, Niu Y, **Lu JJ**, Chen X*. Natural products to prevent drug resistance in cancer chemotherapy: a review. *Ann N Y Acad Sci*. 2017, 1401(1): 19-27.

- 113) Sun W, Wang S, Zhao WW, Wu CH, Guo SH, Gao HW, Tao HX, **Lu JJ**, Wang YT, Chen XP*. Chemical Constituents and Biological Research on Plants in the Genus *Curcuma*. **Crit Rev Food Sci Nutr**. 2017, 57(7): 1451-523.
- 114) Zhao WW, Feng HT, Sun W, Liu K, **Lu JJ**, Chen XP*. Tert-butyl hydroperoxide (t-BHP) induced apoptosis and necroptosis in endothelial cells: Roles of NOX4 and mitochondrion. **Redox Biol**. 2017, 11: 524-34.
- 115) Feng HT, Zhao WW, **Lu JJ**, Wang YT, Chen XP*. Hypaconitine inhibits TGF- β 1-induced epithelial-mesenchymal transition and suppresses adhesion, migration, and invasion of lung cancer A549 cells. **Chin J Nat Med**. 2017, 15(6): 427-35.
- 116) Feng HT, **Lu JJ**, Wang YT, Pei LX*, Chen XP*. Osthole inhibited TGF β -induced epithelial-mesenchymal transition (EMT) by suppressing NF- κ B mediated Snail activation in lung cancer A549 cells. **Cell Adh Migr** 2017, 11(5-6): 464-75.
- 117) Wu KJ, Huang JM, Zhong HJ, Dong ZZ, Vellaisamy K, **Lu JJ**, Chen XP, Chiu P, Kwong DWJ, Han QB, Ma DL*, Leung CH*. A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. **PLoS ONE**. 2017, 12(6): e0177123.
- 118) Kang TS, Wang W, Zhong HJ, Liang JX, Ko CN, **Lu JJ**, Chen XP, Ma DL*, Leung CH*. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity. **Biochim Biophys Acta**. 2017, 1861(2): 256-63.
- 119) Luo XJ, Wu JB, Lv T, Lai YS, Zhang HH, **Lu JJ**, Zhang YH, Huang ZJ*. Synthesis and evaluation of novel O2-derived diazeniumdiolates as photochemical and real-time monitoring nitric oxide delivery agents. **Org Chem Front**. 2017, In Press.
- 120) Wu ZF, Bao H, Zhou FY, Liu JX, Meng FC, Lu F, **Lu JJ**, Zhang QW, Ye Y, Lin LG*. Cytotoxic cassane diterpenoids from the seeds of *Caesalpinia sappan*. **Chin Chem Lett**. 2017, 28: 1711-5.
- 121) Xing L, Lyu JY, Yang Y, Cui PF, Gu LQ, Qiao JB, He YJ, Zhang TQ, Sun M, **Lu JJ**, Xu X*, Liu Y*, Jiang HL*. pH-Responsive de-PEGylated nanoparticles based on triphenylphosphine-quercetin self-assemblies for mitochondria-targeted cancer therapy. **Chem Commun**. 2017, 53(62): 8790-3.
- 122) Li T, Chen X, Chen XP, Ma DL, Leung CH, **Lu JJ***. Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. **Sci Rep**. 2016, 6: 37997.
- 123) Tang ZH, Jiang XM, Guo X, Fong CM, Chen XP, **Lu JJ***. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. **Oncotarget**. 2016, 7(49): 81598-610.
- 124) Tang ZH, Chen X, Wang ZY, Chai K, Wang YF, Xu XH, Wang XW, Lu JH, Wang YT, Chen XP, **Lu JJ***. Induction of C/EBP homologous protein-mediated apoptosis and autophagy by licochalcone A in non-small cell lung cancer cells. **Sci Rep**. 2016, 6: 25241.
- 125) Zhang LL, Xu YL, Tang ZH, Xu XH, Chen X, Li T, Ding CY, Huang MQ, Chen XP, Wang YT, Yuan XF*, **Lu JJ***. Effects of alisol B 23-acetate on ovarian cancer cells: G1 phase cell cycle arrest, apoptosis, migration and invasion inhibition. **Phytomedicine**. 2016, 23(8): 800-9.
- 126) Zhang LL, Tian K, Tang ZH, Chen XJ, Bian ZX, Wang YT*, **Lu JJ***. Phytochemistry and pharmacology of *Carthamus tinctorius* L. **Am J Chin Med**. 2016, 44(2): 197-226.
- 127) Chen X, Wu QS, Meng FC, Tang ZH, Chen XP, Lin LG, Chen P, Qiang WA, Wang YT, Zhang QW*, **Lu JJ***. Chikusetsusaponin IVa methyl ester induces G1 cell cycle arrest, triggers apoptosis and inhibits migration and invasion in ovarian cancer cells. **Phytomedicine**. 2016, 23(13): 1555-65.
- 128) Xu XH, Li T, Fong CM, Chen XP, Chen XJ, Wang YT, Huang MQ*, **Lu JJ***. Saponins from Chinese medicines as anticancer agents. **Molecules**. 2016, 21: 1326.
- 129) Bao H, Zhang LL, Liu QY, Feng L, Ye Y, **Lu JJ***, Lin LG*. Cytotoxic and pro-apoptotic effects of cassane diterpenoids from the seeds of *caesalpinia sappan* in cancer cells. **Molecules**. 2016, 21(6): 791.
- 130) Ren GW, Luo WW, Sun W, Niu YN, Ma DL, Leung CH, Wang YT, **Lu JJ***, Chen XP*. Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells. **Phytomedicine**. 2016, 23(9): 939-47.
- 131) Wang L, Wang YF, Wang XQ, Sun L, Zhou ZZ, **Lu JJ***, Zheng Y*. Encapsulation of low lipophilic and slightly water-soluble dihydroartemisinin in PLGA nanoparticles with phospholipid to enhance encapsulation efficiency and in vitro bioactivity. **J Microencapsul**. 2016, 33(1): 43-52.
- 132) Ding Q, Bao JL, Zhao WW, Lu JJ, Zhu H, Chen XP*. Ethanol enhances cucurbitacin B-induced apoptosis by inhibiting cucurbitacin B-induced autophagy in LO2 hepatocytes. **Mol Cell Toxicol**. 2016, 12(1): 29-36.

- 133) Niu YN, Sun W, **Lu JJ**, Ma DL, Leung CH, Pei LX, Chen XP*. PTEN activation by DNA damage induces protective autophagy in response to cucurbitacin B in hepatocellular carcinoma cells. ***Oxid Med Cell Longev***. 2016, 2016: 4313204.
- 134) Ma GX, Luo WW, **Lu JJ**, Ma DL, Leung CH, Wang YT, Chen XP*. Cucurbitacin E induces caspase-dependent apoptosis and protective autophagy mediated by ROS in lung cancer cells. ***Chem Biol Interact***. 2016, 253: 1-9.
- 135) Guo SH, Luo WW, Liu LJ, Pang XC, Zhu H, Liu AL, **Lu JJ**, Ma DL, Leung CH, Wang YT, Chen XP*. Isocryptotanshinone, a STAT3 inhibitor, induces apoptosis and pro-death autophagy in A549 lung cancer cells. ***J Drug Target***. 2016, 24(10): 934-42.
- 136) Sun W, Bao JL, Lin W, Gao HW, Zhao WW, Zhang QW, Leung CH, Ma DL, Lu JJ, Chen XP*. 2-Methoxy-6-acetyl-7-methyljuglone (MAM), a natural naphthoquinone, induces NO-dependent apoptosis and necroptosis by H₂O₂-dependent JNK activation in cancer cells. ***Free Radic Biol Med***. 2016, 92: 61-77.
- 137) Gao HW, Sun W, Zhao JP, Wu XX, **Lu JJ**, Chen XP*, Xu QM*, Khan IA, Yang SL. Tanshinones and diethyl blechnins with anti-inflammatory and anti-cancer activities from *Salvia miltiorrhiza* Bunge (Danshen). ***Sci Rep***. 2016, 6: 33720.
- 138) Zhang XN, Zhao WW, Wang Y, **Lu JJ**, Chen XP*. The chemical constituents and bioactivities of *Psoralea corylifolia* Linn.: A review. ***Am J Chin Med***. 2016, 44(1): 35-60.
- 139) Wu CH, Bao JL, He CW, Lu JJ, Chen XP*. Cucurbitacin B inhibits proliferation, induces G2/M cycle arrest and autophagy without affecting apoptosis but enhances MTT reduction in PC12 cells. ***Bangladesh J Pharmacol***. 2016, 11: 110-8.
- 140) Hao WH, Zhang XN, Zhao WW, Zhu H, Liu ZY, **Lu JJ**, Chen XP*. Cryptotanshinone induces pro-death autophagy through JNK signaling mediated by reactive oxygen species generation in lung cancer cells. ***Anticancer Agents Med Chem***. 2016, 16: 593-600.
- 141) Ma DL*, Wang WH, Mao ZF, Yang C, Chen XP, **Lu JJ**, Han QB, Leung CH*. A tutorial review for employing enzymes for the construction of G-quadruplex-based sensing platforms. ***Anal Chim Acta***. 2016, 913: 41-54.
- 142) Liu LJ, He B, Miles JA, Wang W, Mao Z, Che WI, **Lu JJ**, Chen XP, Wilson AJ, Ma DL*, Leung CH*. Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds. ***Oncotarget***. 2016, 7(12): 13965-75.
- 143) Lu LH, Wang MD, Mao ZF, Kang TS, Chen XP, **Lu JJ**, Leung CH, Ma DL*. A novel dinuclear iridium(III) complex as a G-quadruplexselective probe for the luminescent switch-on detection of transcription factor HIF-1 α . ***Sci Rep***. 2016, 6: 22458.
- 144) Wang FZ, Xing L, Tang ZH, **Lu JJ**, Cui PF, Qiao JB, Jiang L, Jiang HL*, Zong L*. Co-delivery of doxorubicin and shAkt1 by poly(ethylenimine)-glycyrrhetic acid nanoparticles to induce autophagy-mediated liver cancer combination therapy. ***Mol Pharm***. 2016, 13(4): 1298-307.
- 145) Kim YK, Zhang M, **Lu JJ**, Xu FG, Chen BA, Xing L*, Jiang HL*. PK11195-chitosan-graft-polyethylenimine-modified SPION as a mitochondria-targeting gene carrier. ***J Drug Target***. 2016, 24(5): 457-67.
- 146) Huang MQ*, Xu W, Zhang YP, Liu J, Zhang XQ, Lin J, Peng J, **Lu JJ**. Identification and quantification of the anti-inflammatory constituents in Pian-Tze-Huang by liquid chromatography combined with quadrupole time-of-flight and triple quadrupole mass spectrometry. ***J Chromatogr B***. 2016, 1027: 27-39.
- 147) Liu JL, Wu QS, Wang YT, Zhang QW*, **Lu JJ***. Extraction of Panax Chinese medicines and their anti-cancer effects on HEY ovarian cancer cells. ***J Exp Trad Med For***. 2016, 22(8): 105-10.
- 148) Luo WW, **Lu JJ**, Chen XP*, Wang YT*. The pharmacological effect and its underlying mechanisms of toosendanin: A review. ***Pharmacol Clin Chin Mater Med***. 2016, 32(4): 161-4.
- 149) Tang ZH, Zhang LL, Li T, Lu JH, Ma DL, Leung CH, Chen XP, Jiang HL, Wang YT, **Lu JJ***. Glycyrrhetic acid induces cytoprotective autophagy via the inositol-requiring enzyme 1 α -c-Jun N-terminal kinase cascade in non-small cell lung cancer cells. ***Oncotarget***. 2015, 6(41): 43911-26.
- 150) Tang ZH, Li T, Tong YG, Chen XJ, Chen XP, Wang YT, **Lu JJ***. A systematic review of the anticancer properties of compounds isolated from Licorice (Gancao). ***Planta Med***. 2015, 81: 1670-87.
- 151) Li T, Xu XH, Tang ZH, Wang YF, Leung CH, Ma DL, Chen XP, Wang YT, Chen Y, **Lu JJ***. Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. ***Acta Pharmacol Sin***. 2015, 36(12): 1503-13. (**Outstanding Paper Award 2018**)

- 152) Li T, Tang ZH, Xu WS, Wu GS, Wang YF, Chang LL, Zhu H, Chen XP, Wang YT, Chen Y, **Lu JJ***. Platycodin D triggers autophagy through activation of extracellular signal-regulated kinase in hepatocellular carcinoma HepG2 cells. *Eur J Pharmacol*. 2015, 749: 81-8.
- 153) Wang YF, Li T, Tang ZH, Chang LL, Zhu H, Chen XP, Wang YT*, **Lu JJ***. Baicalein triggers autophagy and inhibits the protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma HepG2 cells. *Phytother Res*. 2015, 29, 674-9.
- 154) Chen XJ, Tang ZH, Li XW, Xie CX, **Lu JJ***, Wang YT*. Chemical constituents, quality control, and bioactivity of *Epimedii Folium* (Yinyanghuo). *Am J Chin Med*. 2015, 43(5): 783-834.
- 155) **Lu JJ***, Lu DZ, Chen YF, Dong YT, Zhang JR, Li T, Tang ZH, Yang Z. Proteomic analysis of HepG2 hepatocellular carcinoma cells treated with platycodin D. *Chin J Nat Med*. 2015, 13(9): 673-9.
- 156) Xu W, Li T, Qiu JF, Wu SS, Huang MQ*, Lin LG, Zhang QW, Chen XP, **Lu JJ***. Anti-proliferative activities of terpenoids isolated from *Alisma orientalis* and their structure-activity relationships. *Anticancer Agents Med Chem*. 2015, 15(2): 228-35.
- 157) Zhang MY, **Lu JJ***, Wang L, Gao ZC, Hu H*, Ung OL, Wang YT. Development of monoclonal antibodies in China: Overview and prospects. *Biomed Res Int*. 2015, 2015: Article ID 168935, 10 pages.
- 158) Gao HW, Sun W, Zhao WW, Hao WH, Leung CH, **Lu JJ**, Chen XP*. Total tanshinones-induced apoptosis and autophagy via reactive oxygen species in lung cancer 95D cells. *Am J Chin Med*. 2015, 43(6): 1265-79.
- 159) Zhang XN, Luo WW, Zhao WW, **Lu JJ**, Chen XP*. Isocryptotanshinone induced apoptosis and activated MAPK signaling in human breast cancer MCF-7 cells. *J Breast Cancer*. 2015, 18(2): 112-8.
- 160) Ren GW, Guo JJ, Li WX, **Lu JJ**, Chen XP*. Cucurbitacin B induces DNA damage and autophagy mediated by reactive oxygen species (ROS) in MCF-7 breast cancer cells. *J Nat Med*. 2015, 69(4): 522-30.
- 161) Ding Q, Bao JL, Zhao WW, Hu YY, **Lu JJ**, Chen XP*. Natural autophagy regulators in cancer therapy: A review. *Phytochem Rev*. 2015, 14(1): 137-54.
- 162) Lu L, Liu LJ, Chao WC, Zhong HJ, Wang M, Chen XP, **Lu JJ**, Li RN*, Ma DL*, Leung CH*. Identification of an iridium(III) complex with anti-bacterial and anti-cancer activity. *Sci Rep*. 2015, 5: 14544.
- 163) Wang WH, Kang TS, Wai P, Chan H, **Lu JJ**, Chen XP, Leung CH*, Ma DL*. A label-free G-quadruplex-based mercury detection assay employing the exonuclease III-mediated cleavage of T-Hg 2+ -T mismatched DNA. *Sci Technol Adv Mater*. 2015, 16: 065004.
- 164) Chen SR, Chen XP, **Lu JJ**, Wang Y*, Wang YT*. Potent natural products and herbal medicines for treating liver fibrosis. *Chin Med*. 2015, 10: 7.
- 165) Lai YF, **Lu JJ**, Hu H*, Wang YT. Analysis of the current situation of antitumor drug use in China: A hospital-based perspective. *Ther Innov Regul Sci*. 2015, 49(1): 181-93.
- 166) Zheng Y, Guo JJ, Zhou J, **Lu JJ**, Chen Q, Zhang C, Qing C, Koeffler HP, Tong YG*. FoxM1 transactivates PTTG1 and promotes colorectal cancer cell migration and invasion. *BMC Med Genomics*. 2015, 8: 49.
- 167) Jiang FS, Tian SS, **Lu JJ**, Ding XH, Qian CD, Ding B, Ding ZS, Jin B*. Cardamonin regulates miR-21 expression and suppresses angiogenesis induced by vascular endothelial growth factor. *Biomed Res Int*. 2015, 2015: Article ID 501581, 8 pages.
- 168) Huang MQ*, Zhang YP, Xu SY, Xu W, Chu KD, Xu W*, Zhao HY, **Lu JJ**. Identification and quantification of phenolic compounds in *Vitexnegundo L. var. cannabifolia* (Siebold et Zucc.) Hand.-Mazz. using liquid chromatography combined with quadrupole time-of-flight andtriple quadrupole mass spectrometers. *J Pharm Biomed Anal*. 2015, 108: 11-20.
- 169) Huang MQ*, Wang PJ, Xu SY, Xu W, Xu W, Chu KD, **Lu JJ**. Biological activities of salvianolic acid B from *Salvia Miltiorrhiza* on type 2 diabetes induced by high fat diet and streptozotocin. *Pharm Biol*. 2015, 53(7): 1058-65.
- 170) Xu XH, Li T, Wang YT, **Lu JJ***. Research progress in *Persicae Semen*. *Chin Trad Herb Drugs*. 2015, 46(17): 2649-55.
- 171) Wang YF, Li T, Tang ZH, Chen XP, Wang YT, **Lu JJ***. Progress on the chemical composition and pharmacological activities of *Scutellariae Radix*. *Chin Arch Trad Chin Med*. 2015, 33(1): 206-211.
- 172) Ren GW, Niu YN, **Lu JJ**, Wang YT, Chen XP*. Recent advances in natural product induced DNA damage response in cancer cells. *Chin J Chin Mater Med*. 2015, 40(24): 4797-804. (In Chinese only)

- 173) Chen XP, Tang ZH, Shi Z, **Lu JJ**, Su HX, Chen X, Wang YT*. Current topics on cancer biology and research strategies for anti-cancer traditional Chinese medicine. *Chin J Chin Mater Med*. 2015, 40(17): 3416-22.
- 174) Zhu H*, Liao SD, Shi JJ, Chang LL, Tong YG, Cao J, Fu YY, Chen XP, Ying MD, Yang B, He QJ, **Lu JJ***. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. *Free Radic Biol Med*. 2014, 71: 121-32.
- 175) Tang ZH, Li T, Chang LL, Zhu H, Tong YG, Chen XP, Wang YT, **Lu JJ***. Glycyrrhetic acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. *J Agric Food Chem*. 2014, 62(49): 11910-6.
- 176) Tang ZH, Li T, Gao HW, Sun W, Chen XP, Wang YT, **Lu JJ***. Platycodin D from *Platycodonis Radix* enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells. *Chin Med*. 2014, 9: 16.
- 177) Li T, Xu WS, Wu GS, Chen XP, Wang YT*, **Lu JJ***. Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. *Asian Pac J Cancer Prev*. 2014, 15(4): 1745-9.
- 178) Xu WS, Li T, Wu GS, Dang YY, Hao WH, Chen XP, **Lu JJ***, Wang YT*. Effects of furanodiene on 95-D lung cancer cells: apoptosis, autophagy and G₁ phase cell cycle arrest. *Am J Chin Med*. 2014, 42(1): 243-55.
- 179) Xu WS, Dang YY, Chen XP, **Lu JJ***, Wang YT*. Furanodiene presents synergistic anti-proliferative activity with paclitaxel via altering cell cycle and integrin signaling in 95-D lung cancer cells. *Phytother Res*. 2014, 28(2): 296-9.
- 180) Guo JJ, Zhao WW, Hao WH, Ren GW, **Lu JJ**, Chen XP*. Cucurbitacin B induces DNA damage, G₂/M phase arrest, and apoptosis mediated by reactive oxygen species (ROS) in leukemia K562 cells. *Anticancer Agents Med Chem*. 2014, 14(8): 1146-53.
- 181) Guo JJ, Wu GS, Bao JL, Hao WH, **Lu JJ**, Chen XP*. Cucurbitacin B induced ATM-mediated DNA damage causes G₂/M cell cycle arrest in a ROS-dependent manner. *PLoS One*. 2014, 9(2): e88140.
- 182) Chen XP*, Guo JJ, Bao JL, **Lu JJ**, Wang YT. The Anti-cancer properties of *Salvia Miltiorrhiza Bunge* (Danshen): A systematic review. *Med Res Rev*. 2014, 34(4): 768-94.
- 183) Yang Y, Dang YY, Li Q, **Lu JJ**, Li XW*, Wang YT*. Complete chloroplast genome sequence of poisonous and medicinal plant *Datura stramonium*: Organizations and implications for genetic engineering. *PLoS One*. 2014, 9(11): e110656.
- 184) Huang MQ*, Xu SY, Xu W, Chen DX, Chu KD, Xu W, Peng J, **Lu JJ**. Qualitative and quantitative analysis of the major constituents in Jin-Mu-Gan-Mao tablet by high-performance liquid chromatography with diode-array detection and quadrupole time-of-flight tandem mass spectrometry. *J Sep Sci*. 2014, 37(23): 3497-508.
- 185) Tian SS, Jiang FS, Zhang K, Zhu XX, Jin B, **Lu JJ**, Ding ZS*. Flavonoids from the leaves of *Carya cathayensis sarg.* inhibit vascular endothelial growth factor-induced angiogenesis. *Fitoterapia*. 2014, 92: 34-40.
- 186) Shen YJ, Zhu XX, Yang X, Jin B, **Lu JJ**, Ding B, Ding ZS, Chen SH*. Cardamonin inhibits angiotensin II-induced vascular smooth muscle cells proliferation and migration by down-regulating p38 MAPK, Akt and ERK phosphorylation. *J Nat Med*. 2014, 68(3): 623-9.
- 187) Shen YJ, Zhu XX, Jiang FS, Jin B, Ding B, **Lu JJ**, Ding ZS*. Inhibitory effects of total flavonoids and pure compounds from leaves of *Carya cathayensis* on angiotensin II-induced proliferation and migration in rat vascular smooth muscle cells. *J Exp Trad Med For*. 2014, 20(1): 119-22.
- 188) Wu GS, Song YL, Yin ZQ, Guo JJ, Wang SP, Zhao WW, Chen XP, Zhang QW, **Lu JJ***, Wang YT*. Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway. *PLoS ONE*. 2013, 8(10): e76620.
- 189) Wu GS, Guo JJ, Bao JL, Li XW, Chen XP, **Lu JJ***, Wang YT*. Anti-cancer properties of triterpenoids isolated from *Ganoderma lucidum*—A review. *Expert Opin Investig Drugs*. 2013, 22(8): 981-92.
- 190) Wu GS, **Lu JJ***, Guo JJ, Huang MQ, Gan L, Chen XP, Wang YT*. Synergistic anti-cancer activity by the combination of dihydroartemisinin and doxorubicin in breast cancer cells. *Pharmacol Rep*. 2013, 65(2): 453-9.
- 191) **Lu JJ**, Bao JL, Wu GS, Xu WS, Huang MQ, Chen XP*, Wang YT*. Quinones derived from plant secondary metabolites as anti-cancer agents. *Anticancer Agents Med Chem*. 2013, 13(3): 456-63
- 192) Chen XP*, Pei LX, **Lu JJ**. Filling the gap between traditional Chinese medicine and modern medicine, are we heading to the right direction? *Complement Ther Med*. 2013, 21(3): 272-5.

- 193) Chen XP*, **Lu JJ**, Bao JL, Guo JJ, Shi JS, Wang YT*. Adiponectin: A biomarker for rheumatoid arthritis? *Cytokine Growth Factor Rev.* 2013, 24(1): 83-9.
- 194) Ma ZQ, **Lu JJ**, Xu WS, Chen XP, Hu H, Wang YT*. Analysis of traditional Chinese medicine injections used in the treatment respiratory system-related diseases based on the China market. *Glob J Res Med Plant Indig Med.* 2013, 2(7): 499-508.
- 195) Huang MQ, Xu W, Wu SS*, **Lu JJ**, Chen XP. A 90-day subchronic oral toxicity study of triterpene-enriched extract from *Alismatis Rhizoma* in rats. *Food Chem Toxicol.* 2013, 58: 318-23.
- 196) Li T, Xu WS, LI XW, Chen XP, **Lu JJ***. Advances in pharmacological studies of *Platycodon grandiflorum*. *Pharmacol Clin Chin Mater Med.* 2013, 29(2): 205-8.
- 197) Xu WS, Dang YY, Guo JJ, Wu GS, **Lu JJ***, Chen XP, Wang YT*. Furanodiene induces endoplasmic reticulum stress and presents anti-proliferative activities in lung cancer cells. *Evid Based Complement Alternat Med* 2012, 2012: Article ID 426521, 8 pages.
- 198) Wu GS, **Lu JJ***, Guo JJ, Li YB, Tan W, Dang YY, Zhong ZF, Xu ZT, Chen XP, Wang YT*. Ganoderic acid DM, a natural triterpenoid, induces DNA damage, G₁ cell cycle arrest and apoptosis in human breast cancer cells. *Fitoterapia.* 2012,; 408-14.
- 199) **Lu JJ***, Bao JL, Chen XP, Huang M, Wang YT*. Alkaloids isolated from natural herbs as the anti-cancer agents. *Evid Based Complement Alternat Med.* 2012, 2012: Article ID 485042, 12 pages.
- 200) **Lu JJ***, Yang Z, Lu DZ, Wo, XD, Shi JJ, Lin TQ, Wang MM, Li Y, Tang LH. Dihydroartemisinin-induced inhibition of proliferation in BEL-7402 cells: An analysis of the mitochondrial proteome. *Mol Med Rep.* 2012, 6(2): 429-33.
- 201) **Lu JJ**, Pan W, Hu YJ*, Wang YT*. Multi-target drugs: The trend of drug research and development. *PLoS One.* 2012, 7(6): e40262.
- 202) **Lu JJ**, Chen SM, Ding J*, Meng LH*. Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. *Mol Cell Biochem.* 2012, 360(1-2): 329-37.
- 203) **Lu JJ**, Dang YY, Huang M, Xu WS, Chen XP*, Wang YT*. The anti-cancer properties of terpenoids from *Rhizoma Curcumae*—A review. *J Ethnopharmacol.* 2012, 143(2): 406-11.
- 204) **Lu JJ**, Cai YJ*, Ding J*. The short-time treatment with curcumin sufficiently decreases cell viability, induces apoptosis and copper enhances these effects in multidrug-resistant K562/A02 cells. *Mol Cell Biochem.* 2012, 360(1-2): 253-60.
- 205) Huang M, **Lu JJ***, Huang MQ, Bao JL, Chen XP, Wang YT*. Terpenoids: natural products for cancer therapy. *Expert Opin Investig Drugs.* 2012, 21(12): 1801-18.
- 206) Zhong ZF, Dang YY, Yuan X, Guo W, Li YB, Tan W, Cui JR, **Lu JJ**, Zhang QW, Chen XP*, Wang YT*. Furanodiene, a natural product, inhibits breast cancer growth both in vitro and in vivo. *Cell Physiol Biochem.* 2012, 30(3): 778-90.
- 207) Wu GS, Qian ZM, GuoJJ, Hu DJ, Bao JL, Xie J, Xu WS, **Lu JJ**, Chen XP*, Wang YT*. *Ganoderma lucidum* extract induces G₁ cell cycle arrest, and apoptosis in human breast cancer cells. *Am J Chin Med.* 2012, 40(3): 631-42.
- 208) Chen XP*, Bao JL, Guo JJ, Ding Q, **Lu JJ**, Huang MQ, Wang YT. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. *Anticancer Drugs.* 2012, 23(8): 777-87.
- 209) Huang MQ, Xie YL, Lai XP*, Lin L, Xu YJ, **Lu JJ**, Chen XP. Protection of total flavonoid fraction from *Nervilia fordii* on lipopolysaccharide-induced acute lung injury in rats. *Chin Herb Med.* 2012, 4(4): 287-93.
- 210) Huang MQ, Xie YL, Chen LD, Chu KD, Wu SS, **Lu JJ**, Chen XP, Wang YT, Lai XP*. Anti-diabetic effect of the total polyphenolic acids fraction from *Salvia miltiorrhiza* Bunge in diabetic rats. *Phytother Res.* 2012, 26(6): 944-8.
- 211) **Lu JJ**, Huang MQ, Chen XP, Wang YT*. Progress in the anti-neoplastic effects and mechanisms of dihydroartemisinin. *Chin J Pharmacol Toxicol.* 2012, 26(3): 397-401.
- 212) **Lu JJ**, Huang MQ, Chen XP, Wang YT*. The application of expression proteomics for the anti-cancer drug research and development. *Chin J New Drugs.* 2012, 21(1): 43-47.
- 213) Xu WS, **Lu JJ***, Chen XP, Wang YT*. Anti-cancer drug research and development based on endoplasmic reticulum stress. *Chin Pharmacolog Bull.* 2012, 28(12): 1659-65.
- 214) Shi JJ, **Lu JJ***. The combinational use of artemisinin compounds and other chemotherapeutics should be paid attention. *Chin Pharm.* 2012, 23(19): 1811-3.
- 215) Lai YF, **Lu JJ**, Chen XP, Hu H*, Wang YT*. Analysis of anti-cancer traditional Chinese medicine injections based on the market performance. *Mod Trad Chin Med Mater Med.* 2012, 14(5): 1958-62.

- 216) Chen XP*, **Lu JJ**, Guo JJ, Bao JL, Xu WS, Ding Q, Wang YT. Inspirations from natural products based drug research and development for Chinese medicine research-Analysis of natural products records in TTD. *Acta Pharm Sin.* 2012, 47(11): 1423–7.
- 217) Jia L, **Lu JJ**, Zhou WY, Shi JJ, Wo XD*. Immunoregulatory effect of polysaccharides from *Platycodon grandiflorum* A. DC on immunosuppressive mice induced by cyclophosphamide. *Food Mach.* 2012, 28(3): 112-114.
- 218) Bao JL, **Lu JJ**, Chen XP*, Wang YT*. The research progress in the anti-tumor effects and mechanisms of matrine and oxymatrine. *Trad Chin Drug Res Clin Pharmacol.* 2012, 23(3): 369-373.
- 219) Huang MQ*, Xu W, Chu KD, **Lu JJ**, Chen XP, Wang YT. Recent advances on Chinese medicine and active ingredients in ameliorating insulin resistance via GLUT4 translocation. *Chin J Exp Trad Med For.* 2012, 18(16): 343-6.
- 220) **Lu JJ**, Cai YJ*, Ding J*. Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells. *Mol Cell Biochem.* 2011, 354(1-2): 247-52.
- 221) **Lu JJ**, Chen SM, Zhang XW, Ding J*, Meng LH*. The anticancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. *Invest New Drugs.* 2011, 29(6): 1276-83.
- 222) Tan W, **Lu JJ**#, Huang MQ, Li YB, Chen MW, Wu GS, Gong J, Zhong ZF, Xu ZT, Dang YY, Guo JJ, Chen XP*, Wang YT*. Anti-cancer natural products isolated from Chinese medicinal herbs. *Chin Med.* 2011, 6: 27.
- 223) Wang Y, **Lu JJ**, He L, Yu Q*. Triptolide (TPL) Inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). *PLoS One.* 2011, 6(9): e23993.
- 224) Deng F*, **Lu JJ**, Liu HY, Lin LP, Ding J, Zhang JS. Synthesis and antitumor activity of novel salvicine analogues. *Chin Chem Lett.* 2011, 22(1): 25–8.
- 225) Fu S, **Lu JJ**, Chen XP, Wang YT*. The progress of anti-cancer terpenoids from *Rhizoma Curcumae*. *West Chin J Pharm Sci.* 2011, 26(6): 604-6.
- 226) Jia L, Wo XD, **Lu JJ***, Wang MM, Zhu XS. Extraction and purification of polysaccharides from *Platycodon grandiflorum* A. DC. *J Biol.* 2011, 28 (2): 21-4.
- 227) Jia L, **Lu JJ**, Lu DZ, Shi JJ, Zhou WY, Wo XD*. Purification and content determination of the polysaccharides from *Platycodon grandiflorum*. *Chin Agr Sci Bull.* 2011, 27(17): 83-6. (In Chinese only)
- 228) **Lu JJ**, Meng LH*, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J*. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. *Biochem Pharmacol.* 2010, 80(1):22-30.
- 229) Pan QY, Wang SZ, **Lu JJ**, Meng LH*, Yao ZJ*. Synthesis of N₁₁-anchoring biotinylated artemisinin derivatives and their preliminary biological assessment. *Sci China B.* 2010, 53(1):119-24.
- 230) **Lu JJ***. Progress in the research on the anti-cancer activity of artemisinin compounds. *Chin Pharmacolog Bull.* 2010, 26(6): 818-20.
- 231) Zhu H, Miao ZH*, Huang M, Feng JM, Zhang ZX, **Lu JJ**, Cai YJ, Tong LJ, Xu YF, Qian XH, Ding J*. Naphthalimides induce G2 arrest via the ATM-activated Chk2-executed pathway in HCT116 cells. *Neoplasia.* 2009, 11(11):1226-34.
- 232) **Lu JJ**, Meng LH*, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J*. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. *Cancer Biol Ther.* 2008, 7(7):1017-23.
- 233) Cai YJ, **Lu JJ**, Zhu H, Xie H, Huang M, Lin LP, Zhang XW, Ding J*. Salvicine triggers DNA double-strand breaks and apoptosis by GSH-depletion-driven H₂O₂ generation and topoisomerase II inhibition. *Free Radic Biol Med.* 2008, 45(5): 627-35.
- 234) Xin ZQ, **Lu JJ**, Ke CQ, Hu CX, Lin LP, Ye Y*. Constituents from *Clausena excavata*. *Chem Pharm Bull.* 2008, 56(6): 827-30.
- 235) Zhou J, Chen Y, Lang JY, **Lu JJ**, Ding J*. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. *Mol Cancer Res.* 2008, 6(2): 194-204.
- 236) Cai YJ, **Lu JJ**#, Miao ZH, Lin LP, Ding J*. Reactive oxygen species contribute to cell killing and P-glycoprotein downregulation by salvicine in multidrug resistant K562/A02 cells. *Cancer Biol Ther.* 2007, 6(11):1794-9.

- 237) Tao ZJ, Zhou YL, **Lu JJ**, Duan WH*, Qin YX, He XX, Lin LP, Ding J*. Caspase-8 preferentially senses the apoptosis-inducing action of NG-18, a gambogic acid derivative, in human leukemia HL-60 cells. *Cancer Biol Ther* 2007, 6(5):691-6.
- 238) Gong JF*, Shao LX, **Lu JJ**, Yao FY. Effects of soybean phospholipids on contents of fatty acids in erythrocyte membranes and brain of mice. *J ZJNU*. 2004, 27(1):72-5.

• MONOGRAPHS / BOOK CHAPTERS

- 1) Essay Writing in Pharmacy and Pharmaceutical Science. *People's Medical Publishing House Co. LTD*. ISBN: 978-7-117-29706-6. January 2021.
- 2) Pharmacology in Chinese medicines (3rd Edition). *Shanghai Scientific & Technical Publishers*. ISBN: 978-7-5478-4239-3/R·1738. January 2019.
- 3) Advances of Chinese medicines for cancer therapy. *People's Medical Publishing House Co. LTD*. ISBN: 978-7-117-16227-2/R·16228. October 2012.

HONORS AND AWARDS

- 1) Outstanding Contribution Award for Chinese Journal of Natural Medicines (2020)
- 2) Outstanding Reviewer Award for Acta Pharmacologica Sinica (2018 & 2020)
- 3) Outstanding Paper Award for Acta Pharmacologica Sinica (2018)
- 4) CNPHARS Annual Young Pharmacologists Award (2016)
- 5) Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2014)
- 6) Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2012)
- 7) 2nd Prize for the 8th Annual Meeting of Shanghai Pharmacological Society (2007)
- 8) Outstanding Poster Presentation Award for SIMM Annual Meeting (2007)
- 9) Excellent Student of Chinese Academy of Sciences (2006)
- 10) Outstanding Graduate of Zhejiang Province (2004)

PROFESSIONAL ACTIVITIES

• PROFESSIONAL MEMBER

- 1) Macau Association of Precision Medicine (Vice President of the Council)
- 2) International Society for Chinese Medicine (Director of the Academic Department)
- 3) International Association of Quality Research in Chinese Medicine (Member of the Council)
- 4) Chinese Association of Integrative Medicine (Committee Member for the Chinese Medicine Branch)
- 5) Chinese Pharmacological Society (Young Committee Member for the Pharmacology of Chinese Medicine and Natural Medicine Branch)
- 6) China Association of Traditional Chinese Medicine (Young Committee Member for the Experimental Pharmacology of Chinese Medicine Branch)
- 7) Guangdong Provincial Anticancer Association (Committee Member for the Anticancer Drugs Branch)
- 8) Guangdong Pharmacological Society (Committee Member for the Oncological Pharmacology Branch)
- 9) Moon Chun Memorial College, University of Macau (Affiliate)

• PEER REVIEWER (PROJECT)

- 1) National Natural Science Foundation of China
- 2) Zhejiang Provincial Natural Science Foundation
- 3) Academic Degree & Graduate Education Evaluation of MOE
- 4) China Adolescents Science & Technology Innovation Contest

• EDITORIAL / YOUTH EDITORIAL BOARD MEMBER

- 1) Translational Oncology (SCI)
- 2) Anti-Cancer Agents in Medicinal Chemistry (SCI)
- 3) Chinese Journal of Natural Medicines (SCI)
- 4) Molecular Medicine Reports (SCI)
- 5) Chinese Medicines (SCI)
- 6) Current Molecular Pharmacology (SCI)
- 7) World Journal of Traditional Chinese Medicine
- 8) Clinical Complementary Medicine and Pharmacology

- 9) Pharmacological Research - Modern Chinese Medicine
- 10) Chinese Journal of Cancer Prevention and Treatment
- 11) Journal of Jiangsu University (Medicine Edition)

- **PEER REVIEWER (JOURNAL)**

As a reviewer for more than 100 scientific journals, such as,

- 1) Acta Pharmaceutica Sinica B
- 2) Acta Pharmacologica Sinica
- 3) Autophagy
- 4) Biochemical Pharmacology
- 5) Drug Discovery Today
- 6) Free Radical Biology and Medicine
- 7) Journal of Experimental & Clinical Cancer Research
- 8) Pharmacological Research
- 9) Pharmacology & Therapeutics
- 10) Phytotherapy Research

Won the honors of outstanding reviewer in multiple journals, such as,

- 1) Acta Pharmacologica Sinica
- 2) Chinese Journal of Natural Medicines
- 3) European Journal of Pharmacology
- 4) Journal of Ethnopharmacology
- 5) Phytomedicine

- **INVITED TALK**

- 1) Seminar Series: Focus on Clinical Quality Development, Beijing (Jul 29, 2024). Anticancer research of natural products from traditional Chinese medicine: Current situation and prospect (Online)
- 2) The 1st Guangdong-Hong Kong-Macao Greater Bay Area Forum on Integrated Chinese and Western Medicine in the Treatment of Cancer, Macao (Jul 14, 2024). Anticancer research of natural products from traditional Chinese medicine: Current situation and prospect
- 3) The 2nd Guangdong-Hong Kong-Macao Conference for Pharmaceutical Innovation and Development, Guangzhou (May 31, 2024). Anticancer research of natural products: Current situation and prospect
- 4) IPSCON 2023-53rd Annual Conference of Indian Pharmacological Society (Dec 14, 2023). Anti-cancer potential of natural products: Cancer cells and immune microenvironment. (Online)
- 5) 2023 Annual Meeting of the Chinese Medicine Experimental Pharmacology Association China Association of Chinese Medicine, Fuzhou (Nov 9, 2023). Anticancer research of traditional Chinese medicine and natural products: Cancer cells and immune microenvironment
- 6) 2023 Editorial Board Meeting for Chinese Journal of Natural Medicines, Nanjing (Oct 21, 2023). Anticancer research of traditional Chinese medicine and natural products: Cancer cells and immune microenvironment
- 7) Cuiheng New District Bio-pharmaceutical Industry Talent Summit Forum, Zhongshan (Sep 26, 2023). Anticancer research of traditional Chinese medicine and natural products: Cancer cells and immune microenvironment
- 8) 2023 Jiangsu Province Summit Forum on Precision Medicine and Integrated Innovation, Wuxi (Sep 22, 2023). Anticancer study of natural products based on combination drugs
- 9) 2023 Annual Conference for Guangdong Immunology Society, Zhuhai (Sep 16, 2023). Anticancer exploration of combination drugs based on immune checkpoint
- 10) The 2nd Sichuan-Macao Health Management Industry Development Forum, Cancer Precision Prevention and Control Conference, Chengdu (Sep 12, 2023). Application of natural products from Chinese medicine for anticancer research: Practice and consideration
- 11) International Conference on Natural Products & the 3rd Wudang International Traditional Chinese Medicine Forum, Shiyang (Aug 22, 2023). Potential application of polysaccharides derived from Chinese medicines in anti-tumor immunity
- 12) The 7th Acta Pharmaceutica Sinica Frontier Forum on Pharmacy, Haikou (Apr 8, 2023). Anticancer studies of natural products based on combination strategies
- 13) Sugar Science and Greater Bay Area Traditional Chinese Medicine Industry Development Forum,

- Zhuhai (Mar 25, 2023). The polysaccharide isolated from plant enhances the anticancer effect of PD-L1 antibody by regulating the microenvironment
- 14) Tianjin University of Traditional Chinese Medicine, Tianjin (Dec 18, 2022). Anticancer studies of natural products based on combination strategies (Online)
 - 15) The 15th Binghu Forum (Hubei University of Chinese Medicine), Wuhan (Dec 7, 2022). Anticancer studies of natural products based on combination strategies (Online)
 - 16) The 4th Sino-CPLP Symposium on Natural Medicine and Biodiversity Resources & the International Forum on Research and Development of Traditional Chinese Medicine Industry, Macao (Dec 3, 2022). Anticancer studies of natural products based on combination strategies
 - 17) The 3rd National Academic Conference of Chinese Pharmacological Society Pharmacoeconomic Committee & the 7th International Conference on Epigenetic Drug Development, Guangzhou (Dec 3, 2022). Identification of new targets and combination strategies for non-small cell lung cancer (Online)
 - 18) The 19th Academic Seminar of the Chinese Medicine Branch of Fujian Association of Traditional Chinese Medicine, Fuzhou (Nov 26, 2022). Anticancer combination strategies based on immune checkpoints: Do Chinese medicines have a chance? (Online)
 - 19) Beijing University of Chinese Medicine, Beijing (Nov 22, 2022). Anticancer studies of natural products based on combination strategies (Online)
 - 20) Greater Bay Area Traditional Chinese Medicine Inheritance and Innovation Development Summit Forum, Shenzhen (Nov 19, 2022). Anticancer studies of natural products based on combination strategies (Online)
 - 21) 2022 Annual Meeting of the Chinese Medicine Experimental Pharmacology Association China Association of Chinese Medicine, Nanjing (Nov 11, 2022): Combination strategies based on immune checkpoints for cancer therapy (Online)
 - 22) 2022 Shanghai University International Forum for Young Scholars, Shanghai (Nov 4, 2022): Combination strategies based on immune checkpoints: Preclinical study (Online)
 - 23) USYD-ZJU Eye and Cancer Joint Seminar: Drug Development in Eye Diseases and Cancers, Sydney & Hangzhou (Nov 2, 2022). Combination strategies based on immune checkpoints: Preclinical study (Online)
 - 24) Jiangmen Central Hospital (Pengjiang), Jiangmen (Oct 17, 2022). Combination strategies based on immune checkpoints: Preclinical study (Online)
 - 25) The 2nd Macau Anti-Cancer Association Annual Symposium, Macao (Oct 16, 2022). Combination strategies based on immune checkpoints: Preclinical study
 - 26) 2022 Annual Meeting for Guangdong-Hong Kong-Macao Joint Lab on Chinese Medicine and Immune Disease Research, Guangzhou (Sep 18, 2022). The regulation of tumor microenvironment and immune checkpoints by natural products derived from Chinese medicine (Online)
 - 27) The 291st Wuya Forum & 22nd Baicao Forum for Shenyang Pharmaceutical University, Shenyang (Apr 22, 2022): Natural products for cancer therapy: Regulation of immune microenvironment (Online)
 - 28) The 3rd Life Science High-end Academic Symposium of Shantou University, Shantou (Jan 8, 2022): Natural products for cancer therapy: Where are we heading? (Online)
 - 29) The 18th Academic Symposium of the Chinese Medicine Branch of the Fujian Association of Chinese Medicine, Fuzhou (Dec 26, 2021): Chinese medicine: Inheritance, innovation and international expansion (Online)
 - 30) I Drug Discovery Online Forum (Dec 8, 2021): Natural products for cancer therapy: Where are we heading? (Online)
 - 31) The 1st annual meeting of the MOE-FSCPO, Macao (Dec 1, 2021): Natural products for cancer therapy: Where are we heading?
 - 32) ZCMU-UM Innovation Forum of Chinese Medicine, Hangzhou (Nov 13, 2021): Natural products in combating lung cancer: active compounds discovering & combination strategies (Online)
 - 33) Guangdong-Hong Kong-Macao Traditional Chinese Medicine Technology Summit Forum & the First Guangdong-Hong Kong-Macao Youth TCM Inheritance and Innovation Seminar, Guangzhou (Oct 30-31, 2021): c-MYC-mediated TRIB3/P62⁺ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2
 - 34) 24 Solar Terms and Life Health & TCM Development International Forum, Jinhua (Oct 24, 2021): Natural products from Chinese medicines for anti-cancer drug discovery (Online)
 - 35) The 17th Annual Meeting of the Chinese Medicine Experimental Pharmacology Association China

- Association of Chinese Medicine, Kunming (Oct 15, 2021): c-MYC-mediated TRIB3/P62⁺ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2 (Online)
- 36) The 20th Radiology Conference & the 10th Imaging Technology Conference of the Guangdong Medical Association, Zhuhai (Aug 15, 2021): Discovery of new anti-lung cancer targets & Research on combination treatment (Online)
 - 37) Fighting Lung Cancer Online Forum (Apr 4, 2021): Natural products in combating lung cancer: Active compounds discovering & combination strategies (Online)
 - 38) 2020 Annual Tumor Immunotherapy and Targeted Therapy Seminar, Guangzhou (Dec 19-20, 2020): Non-small cell lung cancer: Multi-target-based combination therapy (Online)
 - 39) The 16th Annual Meeting of the Chinese Medicine Experimental Pharmacology Association China Association of Chinese Medicine, Kunming (Nov 20-23, 2020): Natural products in anticancer drug discovery: Strategies and perspectives (Online)
 - 40) 2020 National Chinese Medicine Rational Application and Health Product Development Forum, Taiyuan (Nov 6-8, 2020): Natural products in anticancer drug discovery: Strategies and perspectives
 - 41) 2020 Innovational Drug R&D Summit Forum, Jinhua (Oct 30-31, 2020): Natural products in anticancer drug discovery: Strategies and perspectives
 - 42) Zhejiang University, Hangzhou (Dec 26, 2019): The resistant mechanisms of Osimertinib and immune checkpoint regulators from small molecular compounds
 - 43) 2019 National Forum on Comprehensive Utilization of TCM Resources & Research and Application of TCM, Lanzhou (Nov 29-Dec 1, 2019): The progress of pharmacological activities for *Platycodonis Radix*
 - 44) Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou (Nov 29, 2019): Natural products for anticancer drug discovery
 - 45) Chinese Journal of Natural Medicines Young Scholars Forum, Guangzhou (Nov 15-17, 2019): The pharmacological activities of nagilactones
 - 46) The 5th International Week of Chengdu University, Chengdu (Oct 15-18, 2019): Natural products for anticancer drug discovery
 - 47) The 1st International Conference on Natural Toxicology and Pharmacology, Guangzhou (Aug 7-11, 2019): Natural products for anticancer drug discovery
 - 48) Hubei University of Chinese Medicine, Wuhan (May 20, 2019): Anticancer studies on natural products from Chinese medicines: Practice and thinking
 - 49) International Symposium on Good Pharmacology Practice for Chinese Medicines & the 2nd International Symposium on Wudang Local Chinese Medicines, Shiyan (May 17-20, 2019): Anticancer studies on natural products from Chinese medicines: Practice and thinking
 - 50) Chinese Journal of Natural Medicines Young Scholars Forum, Hangzhou (Apr 27-28, 2019): Anticancer activities of natural products from Chinese medicines
 - 51) Chinese Society of Biotechnology Young Scientists Forum IV, Shanghai (Apr 19-21, 2019): Anticancer studies on natural products derived from Chinese medicines
 - 52) Northwestern Polytechnical University, Xian (Apr 18, 2019): Anticancer studies on natural products derived from Chinese medicines
 - 53) The 8th Training Course in Chinese Medicine Quality Assurance, Macao (Apr 12, 2019): Drug screening
 - 54) The 4th Cross-Strait, Hong Kong and Macao Great Health Industry Development Forum, Haerbin (Feb 21-24, 2019): Anticancer studies on natural products: Practice and thinking
 - 55) Tenth People's Hospital of Tongji University, Shanghai (Dec 26, 2018): Anti-lung cancer drug discovery from natural products
 - 56) The 4th Mogan Mountain International Summit on Green Pharmaceuticals, Deqing, (Nov 29-30, 2018): Anticancer drug discovery from natural products
 - 57) 2018 National Chinese Medicine Rational Application and Health Product Development Forum, Hangzhou (Nov 2-4, 2018): Anticancer drug discovery from Chinese medicines
 - 58) The 3rd International Symposium on Phytochemicals in Medicine and Food, Kunming (Aug 25-30, 2018): Investigation on anti-cancer effects and mechanisms of a norditerpenoid from seeds of *Podocarpus nagi*
 - 59) International Conference on Medicinal Plants and Bioeconomy & The 1st Sino-CPLP Symposium on Natural Products and Biodiversity Resources, Macao (Aug 22-24, 2018): Anticancer effects and mechanisms of nagilactone E
 - 60) The 5th National Symposium on Frontier Technology and Development of Pharmacognosy, Xining (Aug 10-12, 2018): Investigation of the pharmacological effects and mechanisms of a norditerpenoid from

seeds of *Podocarpus nagi*

- 61) Holistic Integrative Pharmacology: 2018 Harbin Summit of Chinmedomics and Drug Metabolism, Haerbin (Jun 22-24, 2018): Investigation on anti-cancer effects and mechanisms of a norditerpenoid from seeds of *Podocarpus nagi*
- 62) China Pharmaceutical University, Nanjing (Jun 13, 2018): The potential function of MLKL in apoptosis
- 63) Fujian Agriculture and Forestry University, Fuzhou (Nov 20, 2017): Anti-cancer activities of natural products and the combinational therapies
- 64) Fujian University of Traditional Chinese Medicine, Fuzhou (Nov 20, 2017): Anti-cancer activities of natural products and the combinational therapies
- 65) The 15th National Lung Cancer Academic Conference, Nanchang (Oct 26-28, 2017): Osimertinib (AZD9291) decreases PD-L1 in EGFR-mutated non-small cell lung cancer cells
- 66) ICMAN IUPHAR Natural Products, Aberdeen (Sep 27-29, 2017): The effects and mechanisms of two main constituents from *Glycyrrhiza uralensis* Fisch-induced autophagy in non-small cell lung cancer
- 67) International Symposium on Quality and Efficacy of Chinese Medicines, Shiyao (Aug 3-6, 2017): Natural autophagy regulators for lung cancer treatment
- 68) NSFC-FDCT Frontier Subjects Seminar: Cancer Science, Guangzhou (Jun 18-20, 2017): The combinational strategies for non-small cell lung cancer (NSCLC) treatment
- 69) The 15th National Symposium on Cancer Pharmacology and Clinical Chemotherapy, Hangzhou (Apr 28-May 1, 2017): Osimertinib induces autophagy in cancer cells and the characteristics of its resistant cells
- 70) The 2nd International Symposium on Phytochemicals in Medicine and Food, Fuzhou (Apr 6-10, 2017): Platycodin D, a natural product isolated from *Platycodonis Radix*, displays potential anticancer effects as single or combination therapy
- 71) Guangdong Society of Biochemistry and Molecular Biology 2016 Shantou University Life Science Advanced Symposium, Shantou (Dec 29, 2016): A novel combination approach targeting AKT for the treatment of NSCLC and the characterization of osimertinib-resistant NSCLC cell line
- 72) The 12th Annual Meeting of the Chinese Medicine Experimental Pharmacology Association China Association of Chinese Medicine, Changsha (Oct 19-22, 2016): Screening and mechanism study of natural autophagy regulators for cancer treatment
- 73) The 15th Meeting of Consortium for Globalization of Chinese Medicine (CGCM), Taipei (Aug 22-25, 2016): Garcinone E exerts anticancer properties on ovarian cancer cells
- 74) Minzu University of China, Beijing (Nov 4, 2015): Screening and mechanism study of anticancer natural products and autophagy regulators
- 75) China Pharmaceutical University, Nanjing (May 25, 2015): Screening and mechanism study of anticancer natural products and autophagy regulators
- 76) The 14th National Oncological Pharmacology and Chemotherapy Academic Conference, Shenyang (Apr 24-27, 2015): Glycyrrhetic acid triggers a protective autophagy in lung and liver cancer cells dependent on different mechanisms
- 77) The 28th International Symposium on the Chemistry of Natural Products & the 8th International Conference on Biodiversity, Shanghai (Oct 19-24, 2014): Development of anticancer drugs from Traditional Chinese Medicine and natural products
- 78) Hubei University of Chinese Medicine, Wuhan (Apr 20, 2014): DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal
- 79) Zhejiang Chinese Medical University, Hangzhou (Jun 18, 2013): Anti-cancer properties of triterpenoids isolated from Chinese medicines
- 80) Guiyang College of Traditional Chinese Medicine, Guiyang (May 26, 2013): Anti-breast cancer properties of triterpenoids isolated from *Ganoderma lucidum*
- 81) The 15th annual meeting of China association for science and technology, Guiyang (May 25-27, 2013): Anti-breast cancer properties of triterpenoids isolated from *Ganoderma lucidum*
- 82) The 2nd Training Course in Chinese Medicine Quality Assurance, Macao (Apr 16, 2013): Drug screening
- 83) Chinese Medicine Development Seminar for Portuguese-Speaking Countries, Macao (Nov 12, 2012): Drug screening